Market closed

PTC Therapeutics/$PTCT

14:30

16:10

17:45

19:25

21:00

1D1W1MYTD1Y5YMAX

About PTC Therapeutics

PTC Therapeutics Inc is a biopharmaceutical company focused on the discovery, development, and commercialization of orally administered, small-molecule therapeutics. Its target area is RNA biology post-transcriptional control processes of the events occurring in a cell when an RNA messenger is copied from DNA during the transcription process. The discovered products address multiple therapeutic areas, including rare disorders, such as nonsense mutations in Duchenne muscular dystrophy and oncology.

Ticker

$PTCT

Sector

Health Care

Trading on

NASDAQ

Industry

Biotechnology

Headquarters

South Plainfield, United States

Employees

1,022

Website

www.ptcbio.com

PTC Therapeutics Metrics

BasicAdvanced

$3.4B

-

-$5.93

0.63 -

Price and volume

Market cap

$3.4B

Beta

0.63

52-week high

$49.44

52-week low

$23.58

Average daily volume

717K

Financial strength

Current ratio

2.098

Quick ratio

2.003

Long term debt to equity

-209.407

Total debt to equity

-235.43

Interest coverage (TTM)

-0.75%

Management effectiveness

Return on assets (TTM)

-5.15%

Return on equity (TTM)

52.54%

Valuation

Price to revenue (TTM)

3.737

Price to book

-3.22

Price to tangible book (TTM)

-2.31

Price to free cash flow (TTM)

-12.276

Growth

Revenue change (TTM)

12.84%

Earnings per share change (TTM)

-31.52%

3-year revenue growth (CAGR)

22.31%

3-year earnings per share growth (CAGR)

-3.01%

What the Analysts think about PTC Therapeutics

Analyst Ratings

Analyst ratings (Buy, Hold, Sell) for PTC Therapeutics stock.

PTC Therapeutics Financial Performance

Income Statement

Revenues and expenses

QuarterlyAnnual

Q3 24

QoQ growth

Revenue

$37B

-39.75%

Net income

$45B

107.52%

Profit margin

37.65%

6.78%

PTC Therapeutics Earnings Performance

Earnings per share (EPS)

Company profitability

QuarterlyAnnual

Q4 23

Q1 24

Q2 24

Q3 24

Q4 24

Actual

$3.69

$2.85

$2.45

$2.42

-

Expected

$3.55

$2.61

$2.05

$2.31

$3.94

Surprise

3.94%

9.20%

19.51%

4.63%

-

PTC Therapeutics News

AllArticlesVideos

PTC Therapeutics Stock Soars on Novartis Licensing Agreement

Investopedia·1 month ago

PTC Therapeutics Inks Licensing Pact With Novartis Worth Up To ~$3 Billion For Huntington's Program

Benzinga·1 month ago

PTC Therapeutics signs up to $1.9 billion licensing deal with Novartis

Reuters·1 month ago

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.

Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $PTCT

$

Capital at risk

Market closed

Upcoming events

No upcoming events

FAQs

What’s the current market cap for PTC Therapeutics stock?

PTC Therapeutics (PTCT) has a market cap of $3.4B as of January 15, 2025.

What is the P/E ratio for PTC Therapeutics stock?

The price to earnings (P/E) ratio for PTC Therapeutics (PTCT) stock is 0 as of January 15, 2025.

Does PTC Therapeutics stock pay dividends?

No, PTC Therapeutics (PTCT) stock does not pay dividends to its shareholders as of January 15, 2025.

When is the next PTC Therapeutics dividend payment date?

PTC Therapeutics (PTCT) stock does not pay dividends to its shareholders.

What is the beta indicator for PTC Therapeutics?

PTC Therapeutics (PTCT) has a beta rating of 0.63. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.